Clinical Trial Detail

NCT ID NCT04119024
Title Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

melanoma

Therapies

Aldesleukin + Anti-IL13RA2 CAR T cells + Cyclophosphamide + Fludarabine

Age Groups: adult senior

No variant requirements are available.